Stifel analyst Paul Matteis reiterated a Buy rating and $29.00 price target on Contineum Therapeutics (NASDAQ: CTNM).The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form 4 Contineum Therapeutics, For: Aug 13 Filed by: Huhn Stephen L.August 14, 2024 6:04 PM Contineum Therapeutics, Inc. (CTNM) Misses Q2 EPS by 3cAugust 14, 2024 3:39 PM Form 10-Q Contineum Therapeutics, For: Jun 30August 14, 2024 12:47 PM Form 8-K/A Contineum Therapeutics, For: Aug 13August 14, 2024 12:20 PM Contineum Therapeutics (CTNM) PT Raised to $32 at RBC CapitalAugust 14, 2024 6:24 AM Form 8-K Contineum Therapeutics, For: Aug 13August 13, 2024 4:11 PM Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 13, 2024 4:05 PM